Insmed Chart technicals with my opinion and explanation: YouTube Video below, enjoy!
Month: May 2013
Additional Due Diligence on Insmed ($INSM)
• INSM announced their Q4:12 results, ending the quarter with $92.9 million in cash and short-term investments. INSM anticipates that current cash will be sufficient through Phase III CF and NTM trial data and into mid-2014. The company guided to…
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Rally Insmed
The Orphan Drug Act was passed in January 1983 to encourage companies to develop drugs that treat rare medical conditions. Companies that receive Orphan Drug Status gain certain financial incentives such as a longer period of exclusivity, enhanced patent protection,…
Updated: Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buy
Today, we are going to take a comprehensive look at a small-cap biotech company with several near-term catalysts, a strong cash position, and high insider ownership. I feel with all factors considered, this company can see very good price appreciation…